Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Jefferies Financial Group

Definium Therapeutics (NASDAQ:DFTX) was upgraded by equities researchers at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Thursday, MarketBeat reports.

A number of other analysts have also recently weighed in on DFTX. Jones Trading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target on the stock. Lifesci Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Royal Bank Of Canada raised their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a report on Monday, January 5th. Four investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $35.22.

Definium Therapeutics Price Performance

DFTX opened at $16.88 on Thursday. Definium Therapeutics has a 12-month low of $4.70 and a 12-month high of $18.12. The business’s fifty day simple moving average is $13.76 and its 200-day simple moving average is $11.74. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -8.27 and a beta of 2.57. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, equities research analysts anticipate that Definium Therapeutics will post -1.35 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently made changes to their positions in DFTX. Royal Bank of Canada increased its holdings in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Definium Therapeutics by 77.7% in the second quarter. Blair William & Co. IL now owns 22,218 shares of the company’s stock valued at $144,000 after buying an additional 9,718 shares in the last quarter. CWM LLC raised its holdings in shares of Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after buying an additional 1,796 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Definium Therapeutics by 9.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after buying an additional 1,400 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Definium Therapeutics by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after acquiring an additional 66,663 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.